U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H30N2O7
Molecular Weight 470.5149
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MOEXIPRILAT

SMILES

COC1=CC2=C(CN([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(O)=O)C=C1OC

InChI

InChIKey=CMPAGYDKASJORH-YSSFQJQWSA-N
InChI=1S/C25H30N2O7/c1-15(26-19(24(29)30)10-9-16-7-5-4-6-8-16)23(28)27-14-18-13-22(34-3)21(33-2)12-17(18)11-20(27)25(31)32/h4-8,12-13,15,19-20,26H,9-11,14H2,1-3H3,(H,29,30)(H,31,32)/t15-,19-,20-/m0/s1

HIDE SMILES / InChI

Description

Moexiprilat is the pharmacologically active metabolite of Moexipril. Formation of Moexiprilat is caused by hydrolysis of a Moexipril’s ethyl ester group. Moexiprilat competitively inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the actions of the potent vasoconstrictor angiotensin II and leads to vasodilatation. This agent also prevents angiotensin II-induced aldosterone secretion by the adrenal cortex, thereby promoting diuresis and natriuresis. Moexiprilat showed an extended duration of action owing to a long terminal pharmacokinetic half-life and produced a persistent ACE inhibition.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
2.6 nM [IC50]
2.6 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Moexipril
Primary
Moexipril

Cmax

ValueDoseCo-administeredAnalytePopulation
16 ng/mL
15 mg 1 times / day multiple, oral
MOEXIPRILAT plasma
Homo sapiens
48 ng/mL
30 mg 1 times / day multiple, oral
MOEXIPRILAT plasma
Homo sapiens
154 ng/mL
15 mg 1 times / day multiple, oral
MOEXIPRIL plasma
Homo sapiens
194 ng/mL
30 mg 1 times / day multiple, oral
MOEXIPRIL plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
98 ng × h/mL
15 mg 1 times / day multiple, oral
MOEXIPRILAT plasma
Homo sapiens
136 ng × h/mL
30 mg 1 times / day multiple, oral
MOEXIPRILAT plasma
Homo sapiens
328 ng × h/mL
15 mg 1 times / day multiple, oral
MOEXIPRIL plasma
Homo sapiens
320 ng × h/mL
30 mg 1 times / day multiple, oral
MOEXIPRIL plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
10 h
30 mg 1 times / day multiple, oral
MOEXIPRILAT plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
30%
15 mg 1 times / day multiple, oral
MOEXIPRILAT plasma
Homo sapiens
30%
30 mg 1 times / day multiple, oral
MOEXIPRILAT plasma
Homo sapiens

Doses

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as victim

PubMed

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Hypertension Initial dose: -Patients not receiving diuretic therapy: 7.5 mg orally once a day 1 hour before meals -Patients receiving diuretic therapy: 3.75 mg orally once a day 1 hour before meals Maintenance dose: 7.5 to 30 mg orally per day in 1 or 2 divided doses 1 hour before meals. Maximum dose: 60 mg/day
Route of Administration: Oral
In Vitro Use Guide
In vitro, moexiprilat (active diacid metabolite of moexipril) was a potent inhibitor of ACE in guinea pig serum as well as on purified ACE from rabbit lung with IC50 values of 2.6 and 4.9 nmol/l, respectively. Both, moexipril and moexiprilat inhibited the angiotensin I (ANG I)-induced contractions of rabbit aorta concentration-dependently.